Multicenter study of the impact of Urolift implantation in patients undergoing medical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Autores de IIS La Fe

• Alberto Budía Alba

  Autor

Participantes ajenos a IIS La Fe

• Gonzalez Enguita, C
• Lopez Martin, L
• Herranz Fernandez, L M
• Sinues Ojas, B
• Barrera Rodriguez, C
• Extramiana Cameno, J
• Campa Bortolo, J
• Osca Garcia, J M
• Peran Teruel, M
• Gimeno Argente, V
• Navarro Beltran, A
• Lopez Alcina, E
• Povo Martin, I
• Salvador Pallas Costa, Y
• Ortiz Salvador, J
• Salgado Plonski, J J
• Suarez Sal, P
• Fernandez Arjona, M

Grupos

• Urología

Abstract

INTRODUCTION AND OBJECTIVES: UroLift is a minimally invasive treatment for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The primary objective was to evaluate the impact of UroLift system treatment on quality of life. Secondary objectives assessed the impact on urinary symptoms and sexual function PATIENTS AND METHODS: Patients at 7 Spanish hospitals undergoing pharmacological treatment were offered the choice to continue this treatment or accept surgical intervention. The primary outcome, impact on quality of life, was assessed using the EuroQol-5D-5L questionnaire. Secondary outcomes, including impact on symptoms, erectile function, and ejaculatory function, were evaluated using the IPSS, SHIM-5, and MSHQ-EjD-SF questionnaires, respectively. Outcomes were compared between groups. RESULTS: 91 patients chose UroLiftand 45 continued with pharmacotherapy. At 6 months, a positive impact on quality of life was estimated with UroLift(0.046; SD: 0.02; p=0.067), being significant in subgroups of patients aged >65 years (diff.: 0.034), PSA>2.2 (diff.: 0.108), diabetes mellitus (diff.: 0.023), hypertension (diff.: 0.011) or hypercholesterolemia (diff.: 0.016). The impact on symptomatology was superior with UroLift(-10.07; SD: 1.65; p<0.001), being significant in subgroups aged >65 (diff.: 1.37), prostate >40 cc (diff.: 0.74), PSA>2.2 (diff.: 2.63), and diabetes mellitus (diff.: 1.66), hypertension (diff.: 1.23). Erectile function was not affected (-0.33; SD: 1.99; p=0.868) while ejaculatory function showed a favourable impact (2.98; SD: 1.26; p=0.019). CONCLUSIONS: Minimally invasive UroLiftsystem treatment is associated with a positive impact on quality of life and urinary symptoms without adversely affecting sexual function.

Copyright © 2025 AEU. Published by Elsevier España, S.L.U. All rights reserved.

Keywords

• Benign prostatic hyperplasia; Calidad de vida; Elevación de la uretra prostática; Función sexual; Hiperplasia benigna de próstata; Lower urinary tract symptoms; Prostatic urethral lift; Quality of life; Sexual function; Síntomas del tracto urinario inferior